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Type I insulin-dependent diabetes mellitus (IDDM) remains a major cause of morbidity
and mortality in both pediatric and adult populations, despite significant advances in medical
management. While insulin therapy treats symptoms of acute diabetes, it fails to prevent chronic
complications such as microvascular disease, blindness, neuropathy, and chronic renal failure.
Strict control of blood glucose concentrations delays but does not prevent the onset and
progression of secondary complications (1,2). Although, whole pancreas transplantation restores
physiological blood glucose levels, a continuous process of allograft rejection causes vascular
and exocrine-related complications (4). Recent advances in methods for isolation and
purification of pancreatic islets make transplantation of islet allografts an attractive alternative to
whole pancreas transplantation (3,6). However, immunosuppressive drugs are necessary to
prevent rejection of islet allografts and many of these drugs are known to be toxic to the islets.
Since auto-transplants of isolated islets following total pancreatectomy survive and function in
vivo, it is apparent that a major obstacle to successful clinical islet transplantation is the
immunogenicity of the islet allografts (5).
The Rotating Wall Vessel (RWV) bioreactor technology developed by NASA offers a
unique opportunity to culture cells in simulated microgravity conditions. Solid body rotation
simulates microgravity conditions by randomizing the gravitational vector in a configuration in
which zero headspace, horizontal rotation, and membrane oxygenation simulate the buoyancy
effects of microgravity (7). Ceils are cultured in continuous free fall through the medium and are
exposed to an environment characterized by low shear stress, low turbulence, and high mass
transfer. Many cell types cultured in RWV bioreactors grow as three dimensional organoid
structures with tissue-like organization and function (8-12).
The present studies evaluated the in vivo survival of mouse or rat pancreatic islet
allografts cultured in bioreaetors, or in static Petri dish cultures, in comparison with freshly-
isolated islets. There was no standard immunosuppression used in these studies. In the rat model,
syngeneic Lewis ('LEW; RTll), or allogeneic Buffalo (BUF;RT1 b) or Brown Norway (BN;RTI*)
islets were transplanted to LEW recipients either under the kidney capsule or embolized in the
liver via the portal vein. Following enzymatic digestion of the pancreas with collagenase, islets
were isolated by discontinuous dextran gradient centrifugation (13). Islets separated manually
from acinar tissue fragments were enumerated under a dissecting microscope. Purified donor
islets (LEW, BUF, or BN) were used immediately for transplantation (freshly-isolated) or were
cultured either in stationary Petri dishes (37 C; 5% CO2) or in reusable HARV or STLV RWV
(50 mL) bioreactors (37 C; 5% CO2) with a continuous rotation at 12-14 revolutions/minute
(RPM). Rat islets were cultured in CMRL1066 Medium (GIBCO), supplemented with 1% L-
glutamine, 1% MEM vitamins, 1% HEPES buffer, 10% fetal bovine serum Crlyclone), and
antibiotics. CMLR 1066 medium containing 10% fetal bovine serum fiBS) is a better culture
medium than RPMI 1640 with 10% FBS for culturing rodent islets. Direct microscopic
examination showed that islets cultured in CMRL 1066 medium had fewer islets adhering to the
Petri dish surface. In addition, islets appeared brighter with less darkening---suggesting reduced
central necrosis. Aliquotes of fresh and cultured islets were routinely stained with dithizone
(14; 15) to visualize insulin content. Samples were prepared routinely for hematoxyin and eosin
staining and light microscopic examination of morphology. Following transplant, blood glucose
levels were monitored at intervals to evaluate the efficacy of the transplant to cure diabetes. Two
consecutive blood sugar levels greater than 300 mg/dL glucose were considered a rejection
endpoint.
To increase total number of rat islets, bioreactors were inoculated twice (at days 1 and 3)
with islets cultured previously in Petri dishes. Islets were cultured in bioreactors an average of 11
+ 2 days. In the syngeneic rat transplant model, both Petri dish stationary cultured and bioreactor
cultured LEW islets were capable of curing diabetes in streptozotocin-treated diabetic LEW
recipients,asdocumentedbyagraftmeansurvivaltime(MST)of 95+ 10 days (n=2) and 100 +
0 days (n=2), respectively. In the allogeneic rat transplant model, euglycemia (<300 mg
glucose/alL) was maintained by Petri dish-cultured BUT or BN islets in LEW recipients at 17.5 +
3.5 days (n=2) and 30 days (n=l), respectively. Similarly, the bioreactor-cultured BUT or BN
islets maintained euglycemia in LEW recipients for 15 days (n=l) or for 20 days (n=l),
respectively. Although the rat islet model was successful, we performed the majority of
experiments in mice to increase the yield of islets.
In the allogeneic model, C57BL/10 (H-2 b) pancreatic islets were transplanted under the
kidney capsule into streptozotocin-treated diabetic C3H (I-I-2k) recipients. Streptozotocin-treated
mice with glucose level of 350 mg/dL in two consecutive measurements were considered
diabetic. Mouse islets were isolated using a slight modification of the rat method. Purified
C57BL/10 islets were immediately transplanted (freshly-isolated) or they were cultured in either
stationary Petri dishes (37°C, 5% CO2), or in RWV bioreactors (37°C, 5% CO2) with a
continuous rotation at 12-14 RPM. Islets were cultured in CMRL 1066 medium as described
above. Some euglycemic animals with long term islet transplants were nephrectomized and blood
sugar levels were followed at intervals for 1-2 weeks to determine whether the transplanted islets
were required to maintain normal blood sugar levels.
Culture experiments showed that fibroblastic and other adherent cells present in fresh
preparations were removed by transfer to new Petri dishes during the first week of culture. Such
procedures should eliminate the antigen presenting cells (APC) and lymphocytes (passenger
cells) that express class I1 major histocompatibility complex (M/-IC) antigen. Although class I
MI-IC antigens are expressed on islets and passenger cells, class II MHC antigens are expressed
only on passenger cells. The glucose concentration (Glucose 2 Analyzer, Beckman Instruments,
Fullerton, CA) has been monitored in culture medium of islets cultured in Petri dishes and in
various conditions in bioreactors. Cultured islets were metabolically quiescent, as shown by
intact glucose and stable pH levels during one week of culture. Interestingly, Petri dish-cultured
islets containing fibroblastic cells consumed glucose and displayed lower pH levels. A portable
clinical analyzer (Princeton, N J) confirmed these observations. Insulin, as measured by
radioimmunoassay, was not detectable in medium of islets cultured with 100 mg glueose/ml
concentration.
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Figure 1. Glucose levels in recipients transplanted with bioreactor-cultured allogeneic islets.
The in vi_o results showed that allogeneic mouse pancreatic islets cultured in bivreactors
for seven days prior to transplantation under the kidney capsule cured diabetes for more than 200
days ('N=5) in comparison to only 11.9 + 0.9 days ('N=5) in recipients transplanted with freshly
isolated islets (Fig. 1). Removal of kidneys with transplanted islets following 200 days of
transplantation caused recurrence of diabetes. Following transplantation of various islets
preparations, blood glucose levels were measured twice a week and graft failure was assumed
after two consecutive blood glucose readings greater than 300 mg/dL. Freshly-isolated C57BL/10
allogeneicisletswereacutelyrejectedasconfirmedbytheglucoselevelof 453+ 66.6 mg/dl on
day 11 postgrafting (n=8). In contrast, islets cultured in a bioreactor survived for more than a
MST of 170 days (range 150-220 days; n=6) without any signs of allograft rejection. Only after
the kidneys with islet allografts were removed, did the recipients develop diabetes with a glucose
levels of 371 + 50 mg/dl on day 177 and of 426 + 50 mg/dl on day 180 postgrafting (n=5). These
results document that islets cultured in microgravity environment lost their immunogenicity
or/and become more resistant to the non-specific and alloantigen-specific destruction. In
addition, these results strongly suggest that islets cultured in bioreactors are significantly less
immunogenic in comparison to freshly isolated islets. Therefore, bioreactor-cultured islet
allografts may be transplanted without any immunosuppression to potentially induce a state of
transplantation tolerance. Furthermore, morphological analysis documented that islets cultured in
bioreactors are superior without central necrosis often observed in islets cultured in stationary
Petri dishes. In addition, our preliminary results suggest that fewer bioreactor-cultured islets than
stationary Petri dish-cultured islets were necessary to produce euglycemia (<300 mg glucose/dL).
A.W.,Jyh, ol,_,dlol,_, In our studies, stationary Petri-dish (60 x 15 ram) mouse islet
cultures were initiated with _300-700 freshly-isolated islets in 4 ml
CMLR 1066 medium, there were _200 islets left after 7-day culture.
Bioreactor culture of islets appears to enhance islet aggregation.
However, even with variable aggregation, we found that as few as 20
B.Sllltlon_¢PetrlDishCulture islets cultured in bioreactor were sufficient to cure diabetes for over 100
- " !ii days in allogeneic transplants under the kidney capsule, whereas 500
fresh allogeneic islets were necessary to prevent diabetes for a short time(11.9 5:0.9 days (N=5). The bioreactor culture usually started with
u
ml000 mouse islets in 50 ml total volume, and ended with _300 mixed
c. SlormmctorCult..re individual and clustered islets. The EIN conversion (13) was used to
obtain a uniform equivalent number of freshly-isolated C57BL/10 islets
and islets cultured in bioreactors for transplantation under the kidney
capsule into diabetic syngeneic C57BL/10 recipients. The diameters of
islets were measured in each group (fleshly-isolated, stationary-cultured
or bioreactor-cultured) using an ocular micrometer and a phase contrast
microscope. The islets were evaluated accordingly with their sizes,
namely they were subdivided into diameter classes every 50 lain between
50-350 pm with one class for islets larger than 350 pm in diameter.
Furthermore, the equivalent islet number (EIN) was calculated for each group using a formula
based upon cell volume to convert the different size islets into an equivalent with constant 150
gan islet diameter (13). In particular, the aliquot for each preparation requires 250 equivalent
islets of 150 pan diameter islets (Fig. 2). Freshly-isolated islets displayed very consistent size of
approximately 150 pan in all experiments (Fig. 2A). In contrast, Petri-dish-cultured islets became
smaller in size after 7-days, as documented by the EIN values (Fig. 2B). However, islets cultured
in bioreactor had a variety of sizes, probably because of aggregation of islets in some
experiments (Fig 2C). Since, the average size of a fresh islet is 150 pro, all those above 350 pan
in culture include the aggregates of two or more islets.
In conclusion, our present experiments revealed that bioreactor may be used to culture
pancreatic islets for transplantation. Furthermore, short 7-day culture of islets in bioreaetor
reduces significantly their immunogenieity as documented by long-term allograft survival.
Finally, culture in bioreactor selects strongest islets as documented by limited number of islets
necessary to cure diabetes.
Figure 2. Size of islets
cultured in bioreacor
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